Alembic Receives FDA Approval for Valganciclovir Oral Solution

The U.S. FDA has granted final approval to Alembic Pharmaceuticals Limited for a 50 mg/mL valganciclovir oral solution. This approval provides a new generic option for treating CMV retinitis in patients with AIDS and preventing CMV disease in organ transplant recipients.